Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Bavarian Nordic","sponsor":"Janssen Pharmaceutical","pharmaFlowCategory":"D","amount":"$13.9 million","upfrontCash":"Undisclosed","newsHeadline":"Bavarian Nordic to Manufacture Additional Ebola Vaccines for Janssen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Announces Breakthrough Therapy Designation for its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its RSV Vaccine Candidate in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Provides Update on The Phase 3 Program for Its Covid-19 Booster Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Announces Grant of Prime Eligibility From the European Medicines Agency for Its Rsv Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"company":"Bacthera","sponsor":"Seres Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Bacthera"}]

Bavarian Nordic

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Details:

ABNCoV2, is a next-generation COVID-19 vaccine candidate has shown to be highly immunogenic in relevant preclinical models inducing a durable and highly protective response from a COVID-19 challenge.

Lead Product(s): ABNCoV2

Therapeutic Area: Infections and Infectious Diseases Product Name: ABNCoV2

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 02, 2022

ASK
US

Upload
your Pipeline Activity

Bavarian Nordic

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bavarian Nordic Announces Grant of Prime Eligibility From the European Medicines Agency for Its Rsv Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in O...

Details:

There are no approved vaccines for RSV, and access to PRIME has been granted upon an assessment that the available clinical data overall show the potential of MVA-BN-RSV to address the unmet medical need in the proposed target population.

Lead Product(s): MVA-BN-RSV Vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-BN

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 28, 2022

ASK
US

Upload
your Pipeline Activity

Bavarian Nordic

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bavarian Nordic Provides Update on The Phase 3 Program for Its Covid-19 Booster Vaccine Candidate

Details:

cVLP-RBD (ABNCoV2) is a next-generation COVID-19 vaccine candidate, initially developed by AdaptVac, Denmark using their proprietary capsid virus like particle (cVLP) technology. ABNCoV2 has shown to be highly immunogenic in relevant preclinical models.

Lead Product(s): ABNCoV2

Therapeutic Area: Infections and Infectious Diseases Product Name: cVLP-RBD

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 16, 2022

ASK
US

Upload
your Pipeline Activity

Bavarian Nordic

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its RSV Vaccine Candidate in Older Adults

Details:

First subject vaccinated in Phase 3 clinical trial of MVA-BN RSV for prevention of respiratory syncytial virus in older adults, incorporates five distinct RSV antigens to stimulate a broad immune response against both RSV subtypes.

Lead Product(s): MVA-BN-RSV Vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-BN

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 20, 2022

ASK
US

Upload
your Pipeline Activity

Bavarian Nordic

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bavarian Nordic Announces Breakthrough Therapy Designation for its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

Details:

The designation has been granted upon the assessment of preliminary clinical evidence for MVA-BN RSV, indicating that the vaccine candidate may demonstrate substantial improvement over available therapy on a clinically significant endpoint.

Lead Product(s): MVA-BN-RSV

Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-BN RSV

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 14, 2022

ASK
US

Upload
your Pipeline Activity

Bacthera

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection

Details:

The collaboration with Bacthera will expand the commercial production capacities of SER-109 and provide supply support. SER-109, Seres’ lead product candidate for recurrent Clostridioides difficile infection (rCDI).

Lead Product(s): Firmicute Species Bacterial Spores

Therapeutic Area: Infections and Infectious Diseases Product Name: SER-109

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Seres Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration November 10, 2021

ASK
US

Upload
your Pipeline Activity

Bavarian Nordic

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bavarian Nordic to Manufacture Additional Ebola Vaccines for Janssen

Details:

Bavarian Nordic will manufacture and deliver bulk drug substance of its MVA-BN Filo vaccine, which Janssen has licensed as part of its Ebola vaccine regimen.

Lead Product(s): MVA-BN Filo vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-BN-Filo

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Janssen Pharmaceutical

Deal Size: $13.9 million Upfront Cash: Undisclosed

Deal Type: Agreement June 18, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY